Disclaimer: This analysis was produced using autonomous AI agents and publicly available information. It is intended for informational and educational purposes only and should not be used to make investment decisions. CompetitiveIntelligence.com is an independent publication. For our relationship with Atacana Group, see our About page.
Company Name: AlphaSense, Inc.
Headquarters: New York City, NY
Founded: 2011
Co-Founders: Jack Kokko (CEO), Raj Neervannan (CTO)
Ownership: Private — $7.5B valuation (June 2026)
Total Funding: $1.74B across 16 rounds
Latest Round: $350M Series F (June 3, 2026) — led by Vitruvian Partners, Accenture Ventures, J.P. Morgan Asset Management
ARR: $600M+ confirmed (Q1 2026); $700M+ reported (July 2026)
Revenue Trajectory: $400M (early 2025) → $500M (Oct 2025) → $600M+ (Q1 2026) → $700M+ (July 2026)
Employees: ~3,461 (Sep 2026, Tracxn); ~4,021 (Jun 2026, Revelio Labs)
Enterprise Customers: ~8,000 (Oct 2026)
S&P 100 Penetration: 92%
Top 50 Pharma: 92%
Top Investment Banks: 18 of top 20; 100+ total
Top Consulting Firms: 95%
CEO & Co-Founder — Jack Kokko: Former Morgan Stanley investment banker; founded AlphaSense in 2011
CTO & Co-Founder — Raj Neervannan: Co-founded the platform with Kokko
CFO — Samantha Greenberg: Joined April 2026. Former Goldman Sachs and Citadel investor; CFO at Mint House and ID.me. Oversees capital markets strategy and investor relations
Chief Content Officer — Bob Magri: Named in EIU partnership PR
CISO — Pieter VanIperen: Security leadership for enterprise AI platform
Vitruvian Partners, Accenture Ventures, J.P. Morgan Asset Management, Goldman Sachs, CapitalG (Alphabet), Viking Global Investors, BDT & MSD Partners, D.E. Shaw Ventures, Innovation Endeavors.
Understanding what AlphaSense is trying to become reveals where they'll invest, what markets they'll enter, and which strategic moves to anticipate.
AlphaSense positions itself as "the AI platform redefining market intelligence for the business and financial world". CEO Jack Kokko has described the platform as evolving from a search engine into an autonomous AI execution layer that "owns the decision loop" — the idea that enterprise value equals the sum of decisions a platform supports.
At AlphaSummit 2026, AlphaSense announced that AI agents now perform "99 percent of research activity" on the platform — 2 billion AI actions versus 20 million human actions annualized — signaling a strategic bet that autonomous agents, not human-driven search, are the platform's future.
IPO preparation is underway. In July 2026, The Information reported that AlphaSense had exceeded $700 million in ARR and was working with IPO advisory firm Class V Group while discussing potential listings with underwriters. No S-1 has been filed as of November 2026. Independent analysts point to H1 2027 as the likely IPO window.
The company's revenue trajectory has been steep: $400M in early 2025 → $500M by October 2025 → $600M+ by Q1 2026 → $700M+ by July 2026, representing roughly 40% year-over-year growth. Hiring a capital-markets-experienced CFO in Samantha Greenberg further signals pre-IPO preparation.
AlphaSense is pursuing expansion along three axes simultaneously:
Horizontal: Financial services deepening. Investment banking ARR growing 75% year-over-year with 10,000+ new IB users added in Q3 2026 alone. The company now serves 18 of the top 20 investment banks.
Vertical: Life sciences expansion. The September 2026 launch of Clinical Trial and Drug Data — a unified knowledge graph spanning companies, drugs, indications, trials, regulatory approvals across the US, EU, and China — represents AlphaSense's most significant vertical-specific investment to date. APAC life sciences webinars explicitly target pharma strategy teams using SuperAnalyst for "evidence-backed where-to-play maps".
Geographic: EMEA and APAC. Active London hiring across sales development, enterprise AE, and customer success roles, plus dedicated APAC life sciences programming.
AlphaSense is making several simultaneous technology bets:
AlphaSense has completed four acquisitions in five years: Stream (2021), Sentieo (2022), Tegus (2024), and Carousel (2025). Each acquisition has followed a clear pattern: acquire unique content or capability, then integrate into the unified platform. With $350M in fresh funding and potential IPO capital, continued M&A is likely — particularly in data assets for vertical-specific knowledge graphs (pharma, supply chain, regulatory).
AlphaSense operates as a differentiation leader in Porter's generic strategy framework. It does not compete on price — enterprise packages start at roughly $10,000–$50,000+ per seat annually, with no public pricing. Instead, AlphaSense differentiates on three pillars:
AlphaSense employs an enterprise direct sales model with growing channel distribution:
AlphaSense uses a quote-based, opaque enterprise pricing model — no prices are published on their website. Based on third-party data:
Pricing is the most common customer complaint across review platforms, with users consistently noting high cost and price opacity.
AlphaSense invests heavily in thought leadership and category definition:
Porter's third component examines the mental models that guide a competitor's decisions. When these assumptions are wrong, they create exploitable blind spots.
AlphaSense's self-image: A unified "decision-grade AI platform" that is evolving from a search tool into an always-on autonomous execution layer for business and financial professionals.
Market reality: AlphaSense is unquestionably the dominant platform in market and competitive intelligence — the dual Gartner MQ Leader + Forrester Wave sole Leader recognition is a procurement narrative that's difficult for any competitor to counter. However, the "platform for everything" positioning creates tension: financial services teams, corporate CI practitioners, and pharma market intelligence analysts have fundamentally different workflows, and a single AI agent may struggle to serve all three with the depth that specialized tools provide.
"AI agents will replace analyst workflows." AlphaSense's most consequential bet. Their usage data supports it — 99% of research activity is now AI-driven, with 2 billion AI actions vs. 20 million human. The assumption that may prove wrong: regulated industries (pharma, financial services) may require human-in-the-loop validation for compliance reasons that pure AI automation can't satisfy.
"Content breadth beats content depth." AlphaSense's 500M+ document library is unmatched in breadth. But in verticals like pharma — where specialized databases (Citeline's TrialTrove, Evaluate's pipeline analytics) have decades of curated depth — breadth alone may not be sufficient. Their Clinical Trial and Drug Data launch explicitly targets this gap, but the dataset is new.
"One MCP to rule them all." The SuperAnalyst MCP strategy assumes companies will prefer a single intelligence API over assembling multiple specialized MCPs. AlphaSense claims a 3x cost advantage per correct answer versus fragmented vector-search MCPs. This assumption may hold for general business research but faces pressure from domain specialists offering deeper, cheaper vertical data.
"Premium pricing is sustainable at scale." With per-seat pricing in the $10K–$50K+ range, AlphaSense assumes the market will continue to bear these costs. As AI-native alternatives emerge and open-source models commoditize basic research tasks, this assumption faces increasing pressure — particularly in the mid-market and in price-sensitive geographies.
AlphaSense explicitly positions against Citeline, GlobalData, IQVIA, and Evaluate in their pharma buyer's guide. They focus competitive energy on Bloomberg Terminal (financial data), Gartner (advisory), and traditional research providers.
They appear to pay less attention to emerging AI-native competitors in the CI space, particularly smaller platforms that may not yet register at enterprise scale. They also underplay the risk from generalized AI tools (ChatGPT, Claude, Perplexity) that handle basic research tasks for free.
AlphaSense's biggest historical blind spot was pharma data specificity — for years, the platform lacked structured clinical and regulatory data that pharma CI teams consider table stakes. The September 2026 launch of Clinical Trial and Drug Data addresses this directly. Whether the fix is deep enough — in a market where Citeline, Evaluate, and Cortellis have decades of curated data — remains an open question.
A second blind spot: messaging inconsistency around MCPs. In August 2026, AlphaSense published "Frontier AI Models Need Frontier Context" — an explicitly anti-MCP position arguing that fragmented data connections produce inferior results. Three months later, they launched SuperAnalyst MCP. The pivot is commercially smart but creates narrative confusion for buyers evaluating their architectural commitments.
AlphaSense has evolved from a document search engine into a multi-layered AI platform. As of November 2026, the product architecture includes:
Flagship: SuperAnalyst (launched June 2026) Always-on autonomous AI agent with persistent memory, 24/7 monitoring, AI-led expert call execution, code writing/execution, and decision-ready output generation (investment memos, financial models, dashboards, presentations). Monitors assumptions and auto-updates when conditions change.
SuperAnalyst MCP (launched November 2026) Extends SuperAnalyst outside the platform via Model Context Protocol. Single endpoint exposes the full content library as a delegatable research agent for any external AI system. Claims 3x cost efficiency versus raw vector-search MCPs and 2:1 answer preference over vector-RAG alternatives.
Clinical Trial and Drug Data (launched September 2026) Unified life sciences knowledge graph connecting companies, drugs, indications, trials, targets, and mode of action. Covers US, EU, and China regulatory data. Integrates with SuperAnalyst for autonomous pharma workflows.
Supply Chain Knowledge Graph (launched October 2026) Connects suppliers, customers, components, products, and countries of origin. Source-verified with visual dashboards via SuperAnalyst.
Channel Check Intelligence (launched October 2026) Verdict-first analytical dashboard across 750+ tickers. Daily refresh with KPI aggregates, contrarian call detection, and inflection signals between earnings cycles.
SuperAnalyst Skills Ecosystem (launched October 2026) Pre-built and custom workflow libraries. Users define reusable agentic workflows in natural language. 56 skills submitted during the AlphaSummit hackathon, including pharma-specific workflows like the "PDUFA Signal Tracker".
Additional capabilities: Generative Search, Generative Grid, Smart Summaries, native PowerPoint and Excel add-ins, Sentiment Indices across 15 sectors, 20+ connectors (Gmail, Slack, Teams, Snowflake, etc.), and Due Diligence Workspace.
AlphaSense has 13+ years of domain-specific AI development, which is unusual in a market where most competitors are recent adopters of LLM technology. Key technical capabilities:
With $1.74B in total funding and $700M+ ARR, AlphaSense has substantial investment capacity. However, profitability is undisclosed, and the company is absorbing significant AI inference costs — token consumption reached 54 trillion annualized, 5x from early 2026. Independent analysts note this cost structure is a key variable in IPO readiness.
Analyst coverage is a significant competitive moat. Holding both the #1 Gartner MQ position and the sole Forrester Wave Leader designation means AlphaSense dominates the procurement shortlisting process at large enterprises.
Based on customer reviews, independent analysis, and competitive intelligence:
Price and price opacity are the #1 complaint. Five-figure annual seats and opaque quoting processes are consistently cited across G2, Reddit, and third-party review sites.
Horizontal platform, vertical depth gaps. Pharma is one vertical among many. The Clinical Trial and Drug Data offering is brand new (September 2026) and has not been proven against specialized incumbents with decades of curated datasets.
No scenario analysis or war-gaming capabilities. For CI practitioners — particularly in pharma — the ability to model competitive responses and run scenario simulations is a core workflow that AlphaSense does not currently address.
AI-first, not human+AI hybrid. AlphaSense leans entirely into autonomous agents. Some CI use cases require expert human judgment layered on top of AI research — a capability gap in their current architecture.
Information overload risk. Several reviewers note the "sheer volume of reports and comments can still bury a specific insight" — the same breadth that's a strength can make signal extraction harder.
AI inference cost uncertainty. With 54 trillion tokens consumed annually and growing 5x year-over-year, the cost of running autonomous agents at scale is material. Profitability is undisclosed.
AlphaSense has invested heavily in enterprise-grade security: SOC 2 Type II certified, ISO/IEC 27001 certified, zero data retention in SuperAnalyst, AES-256 encryption at rest, TLS 1.2+ in transit, customer-managed encryption support. Received the highest possible score in Forrester's security criterion.
Based on the analysis of AlphaSense's goals, strategy, assumptions, and capabilities, here's how they're likely to behave over the next 12 months.
IPO in H1 2027. The CFO hire, Class V Group engagement, underwriter discussions, and revenue trajectory all point to a public listing in the first half of 2027. Post-IPO capital will likely accelerate M&A and international expansion.
Deeper pharma vertical investment. Clinical Trial and Drug Data is the beachhead. Expect deeper pharma-specific knowledge graphs (drug pricing, regulatory pathways, commercial analytics) and dedicated pharma sales motions through the Accenture partnership. APAC life sciences webinars already promote SuperAnalyst for "where-to-play maps".
SuperAnalyst Apps launch. Previewed at AlphaSummit 2026 and described as "coming in the coming months," this no-code app creation layer would transform AlphaSense from a research platform into a business application platform.
MCP ecosystem expansion. SuperAnalyst MCP makes AlphaSense a backend intelligence layer for any AI agent ecosystem. Expect partnerships with enterprise AI orchestration platforms and expanded use cases beyond financial research.
Continued M&A. The pattern of 1–2 acquisitions per year is likely to continue. Targets will probably be in specialized content (pharma data, regulatory intelligence, supply chain data) or complementary AI capabilities.
Pre-IPO distraction (now through mid-2027). Management attention will split between product development and IPO roadshow/compliance. Profitability pressure may slow aggressive product investment.
Pharma data depth gap (now through 2027). Clinical Trial and Drug Data is new. For the next 12–18 months, specialized pharma data platforms (Citeline, Evaluate) will have deeper historical coverage and more established data validation workflows.
Mid-market pricing gap. With $10K–$50K+ per seat pricing, AlphaSense leaves a substantial mid-market segment underserved — particularly smaller pharma/biotech companies and lean CI teams that need intelligence tooling but can't justify enterprise pricing.
AI inference cost exposure. The 5x growth in token consumption without disclosed profitability creates a margin risk that could constrain product investment or force pricing increases.
For CI practitioners and buyers evaluating AlphaSense, the following areas warrant ongoing monitoring:
US Monthly Search Volume ("alphasense"): 27,100 (Internal keyword research)
Global Monthly Search Volume: 63,000 (Internal keyword research)
Keyword Cluster Volume: 52,100 (Internal keyword research)
Keyword Difficulty: 45% (Internal keyword research)
CPC: $0 (navigational) (Internal keyword research)
Keyword Variations: 1,731 (Internal keyword research)
alphasense competitors: 320 (20%)
what is alphasense: 320 (42%)
alphasense pricing: est. 200+
alphasense alternatives: est. 150+
alphasense review: est. 100+
This section links to the most recent Vendor Intelligence Feed posts for AlphaSense. Updated as new signals are published.
This profile is maintained as a living document. When new intelligence signals change any of the four Porter components — goals, strategy, assumptions, or capabilities — the relevant sections are updated. For the latest intelligence briefs on AlphaSense, visit the Vendor Intelligence Feed.
© 2026 CompetitiveIntelligence.com. Independent analysis by Alex Von. All factual claims sourced with hyperlinks.